British Columbia's Ministry of Health is limiting the sales of two more diabetes drugs to curb their off-label use for weight ...

All doses of Eli Lilly & Co.’s blockbuster new drugs to treat diabetes and weight loss are available in the US after more than a year and a half of shortages.. The Food and Drug Administration ...

In a trial, the daily GLP-1 pill showed "significant" results and similar side effects to injectable GLP-1 drugs like Ozempic ...

GLP-1 medications offer promising benefits for obesity and diabetes patients, with studies showing reduced heart attack risk and potential applications for addiction treatment.

(Reuters) -All doses of Eli Lilly's weight-loss drug Zepbound and diabetes drug Mounjaro are now available, the U.S. Food and Drug Administration's updated shortage list showed on Friday.

Drugs used for diabetes now in short supply due to people using them for weight loss 02:33. DALLAS (CBSDFW.COM) — Online, you can find video after video of people talking about their experiences ...

Previous studies with semaglutide, the generic form of Wegovy, showed weight loss of 9.6% for people with diabetes, though the two drugs have not been compared directly.

Other GLP-1 drugs, which include semaglutide, sold by Novo Nordisk as Ozempic to treat diabetes and Wegovy for weight loss, can cost more. Many insurance carriers do not cover the cost of weight ...

CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor ...

GLP-1 agonists like Wegovy, Ozempic, and Mounjaro might benefit heart and brain health—but research suggests they might also ...

Another diabetes drug, called Mounjaro, is now gaining attention, with many people using it off-label to lose weight. Some research has found that Mounjaro may be even more powerful than either ...

Ozempic and other drugs for diabetes and weight loss are under new scrutiny after reports of hair loss, suicidal thoughts and other side effects. 24/7 Live Los Angeles Orange County Inland Empire ...